{"schema_version":"secwatch.filing_event.v1","accession":"0001295947-22-000007","form_type":"8-K","ticker":"PBH","cik":"0001295947","company_name":"Prestige Consumer Healthcare Inc.","filed_at":"2022-02-03T23:59:59+00:00","discovered_at":"2026-05-14T18:04:05.816505+00:00","generated_at":"2026-06-27T11:33:38.252443+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"confidence":"high","headline":"Prestige Q3 revenue $274.5M (+14.9% YoY), EPS $0.99 (+22.2%); raises FY22 outlook","bullets":["Revenue $274.5M, up 14.9% YoY; organic growth 8.8% excluding currency and Akorn acquisition.","Diluted EPS $0.99, up 22.2% YoY; FY22 adjusted diluted EPS guidance raised to $4.00-$4.04.","Non-GAAP free cash flow $64.1M in Q3 vs $43.5M prior year; FY22 free cash flow guidance raised to $250M+.","North America OTC segment $240.9M (+14.4%); International OTC $33.6M (+19.3% record).","Paid down $70M debt in Q3; net debt ~$1.5B, covenant leverage ratio 3.9x."],"urls":{"canonical":"https://secwatch.observer/filing/0001295947-22-000007","json":"https://secwatch.observer/filing/0001295947-22-000007.json","markdown":"https://secwatch.observer/filing/0001295947-22-000007.md","text":"https://secwatch.observer/filing/0001295947-22-000007.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1295947/000129594722000007/0001295947-22-000007-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1295947/000129594722000007/pbh-20220203.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T11:33:38.252443+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}